Experienced in Plasmacytoma

Dr. Pamela S. Becker

Hematology
City Of Hope Medical Foundation
1500 Duarte Rd, 
Duarte, CA 
Offers Telehealth
37 Years of Experience
Experienced in Plasmacytoma
City Of Hope Medical Foundation
1500 Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pamela Becker is a Hematologist in Duarte, California. Dr. Becker has been practicing medicine for over 37 years and is rated as an Experienced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Colonoscopy.

Her clinical research consists of co-authoring 157 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030
CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)
Enrollment Status: Terminated
Publish Date: May 17, 2024
Intervention Type: Biological, Drug, Other, Procedure
Study Phase: Phase 1
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data
Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data
Enrollment Status: Completed
Publish Date: June 30, 2022
Intervention Type: Drug, Genetic, Other
Study Phase: Not Applicable
CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing
CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing
Enrollment Status: Terminated
Publish Date: May 09, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Unknown
Publish Date: December 13, 2021
Intervention Type: Drug
Study Drug: CWP232291
Study Phase: Phase 1/Phase 2
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Not Applicable
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

155 Total Publications

Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia.
Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia.
Journal: Cancer
Published: July 13, 2025
Similar Doctors
Distinguished in Plasmacytoma
Dr. Raymundo Romero
Oncology | Hematology
Distinguished in Plasmacytoma
Dr. Raymundo Romero
Oncology | Hematology

Hao Wei Zhang MD Inc

1700 E Cesar E Chavez Ave, Suite 2600, 
Los Angeles, CA 
 (15.1 miles away)
323-264-7238
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Raymundo Romero is an Oncologist and a Hematologist in Los Angeles, California. Dr. Romero is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Plasmacytoma, Anemia, Inflammatory Breast Cancer, and Thrombocytopenia.

Distinguished in Plasmacytoma
Dr. Xiaohui S. Zhao
Hematology
Distinguished in Plasmacytoma
Dr. Xiaohui S. Zhao
Hematology

Regents Of The University Of California

101 The City Dr S, 
Orange, CA 
 (24.0 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances

Xiaohui Zhao is a Hematologist in Orange, California. Dr. Zhao is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Plasmacytoma, Burkitt Lymphoma, Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Tissue Biopsy.

Distinguished in Plasmacytoma
Dr. Hao W. Zhang
Hematology Oncology | Hematology | Oncology
Distinguished in Plasmacytoma
Dr. Hao W. Zhang
Hematology Oncology | Hematology | Oncology

Hao Wei Zhang MD Inc

1700 E Cesar E Chavez Ave, Suite 2600, 
Los Angeles, CA 
 (15.1 miles away)
323-264-7238
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hao Zhang is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Anemia, Plasmacytoma, Choriocarcinoma, and Inflammatory Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Becker's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 12 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile